Intratio
Loading...
Skip to main content
Stock comparison · Signal date 2026-10-30

BCRX vs VCEL: stock comparison and AI forecast

Biocryst Pharmaceuticals Inc (BCRX) and Vericel Corp (VCEL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market

Share
Nasdaq · Biological Products, (No Diagnostic Substances)

BCRX Biocryst Pharmaceuticals Inc

Price
$8.47 -7.5% · 6M
Market Cap
$2.16B
P/E Ratio
–
Size
mid-cap
AI Forecast
NO CURRENT FORECAST
Full analysis →
Nasdaq · Biological Products, (No Diagnostic Substances)

VCEL Vericel Corp

Price
$42.91 +23.6% · 6M
Market Cap
$2.20B
P/E Ratio
116.0x
Size
mid-cap
AI Forecast
NO CURRENT FORECAST
Full analysis →
Model output

Which one does the AI model favor?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

6M · 2026-04-30 → 2026-10-30

Six-month price performance

Closing prices rebased to 100 at the start of the window.

90105120135
BCRX -7.5% VCEL +23.6%
BCRX · VCEL

Key facts

  • BCRX and VCEL have similar market capitalizations ($2.16B and $2.20B).
  • Over the last six months VCEL returned +23.6% and BCRX -7.5%.
  • VCEL turns 7.9% of its revenue into net income, against -40.9% for BCRX.
  • Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals

Fundamentals side by side

Trailing twelve months.

Valuation & Market

MetricBCRXVCEL
Market Cap$2.16B$2.20B
P/E Ratio–115.97x
P/B Ratio–5.94x
EPS$-1.49$0.37
Book Value/Share–$7.23
Revenue/Share$3.68$5.98
FCF/Share$1.46$1.20

Profitability & Margins

MetricBCRXVCEL
ROE–6.5%
ROA-69.0%4.8%
ROIC-89.7%4.0%
Gross Margin97.8%74.6%
Operating Margin-33.3%6.0%
Net Margin-40.9%7.9%
EBT Margin-40.5%8.0%
Tax Rate-0.9%–

Financial Health

MetricBCRXVCEL
Current Ratio2.32x5.04x
Quick Ratio2.29x4.69x
D/E Ratio–0.36x
Financial Leverage–1.36x
Interest Coverage11.9x45.8x
Working Capital$276M$212M

Cash Flow

MetricBCRXVCEL
Operating Cash Flow$376M$70M
Free Cash Flow$373M$62M
Capital Spending-$3M-$8M
OCF Growth YoY2136.6%47.5%
FCF Growth YoY2269.0%–
FCF/Sales39.7%20.1%
CapEx/Sales0.3%2.6%

Operational Efficiency

MetricBCRXVCEL
Asset Turnover1.69x0.61x
Receivables Turnover8.5x4.0x
Inventory Turnover3.5x4.2x
Fixed Assets Turnover103.8x2.9x
Days Sales Outstanding43 days90 days
Days Inventory106 days86 days
Payables Period200 days97 days
Cash Conversion Cycle-51 days80 days

Income Statement

MetricBCRXVCEL
Total Revenue$941M$306M
Operating Income-$313M$18M
Net Income-$385M$24M
R&D Expense$198M$29M
SG&A Expense$337M$181M
Cost of Goods Sold$21M$78M

Dividend & Shareholder Information

MetricBCRXVCEL
Shares Outstanding256M51M
Net Income Growth–240.8%
EPS Growth–27.6%
FAQ

BCRX vs VCEL: stock comparison and AI forecast

Which is bigger, BCRX or VCEL?

BCRX and VCEL have similar market capitalizations ($2.16B and $2.20B).

Which stock performed better over the last six months, BCRX or VCEL?

Over the last six months VCEL returned +23.6% and BCRX -7.5%.

Which one does Intratio's AI model rank higher, BCRX or VCEL?

Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.

Compare

More comparisons

This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.